(E)-oct-2-ene-1-thiol | 111835-86-0

• 分子结构分类: 有机化合物 - 有机硫化合物 - 硫醇
• 英文名称: (E)-oct-2-ene-1-thiol
• CAS: 111835-86-0
• 化学式: C₈H₁₆S
• 分子量: 144.281
• InChiKey: TVLMHTIYSQNKIL-VOTSOKGWSA-N

物化性质

• 沸点：
  130 °C(Press: 30 Torr)
• 密度：
  0.857±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.4
• 重原子数：
  9
• 可旋转键数：
  5
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.75
• 拓扑面积：
  1
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  双(二甲胺基)氯酸磷 、 (E)-oct-2-ene-1-thiol 在 三乙胺 作用下， 以 乙醚 为溶剂， 反应 1.0h， 以82%的产率得到S-(E)-oct-2-enyl N,N,N',N'-tetramethylphosphorodiamidothioate
  参考文献：
  名称：

  Binns, Malcolm R.; Haynes, Richard K.; Lambert, Dale E., Australian Journal of Chemistry, 1987, vol. 40, # 2, p. 281 - 290

  摘要：

  DOI：
• 作为产物：
  描述：

  1-辛烯-3-醇 在 C.I.酸性橙108 作用下， 反应 0.08h， 生成 (E)-oct-2-ene-1-thiol
  参考文献：
  名称：

  Binns, Malcolm R.; Haynes, Richard K.; Lambert, Dale E., Australian Journal of Chemistry, 1987, vol. 40, # 2, p. 281 - 290

  摘要：

  DOI：

文献信息

• [EN] LANTHIONINE C-LIKE PROTEIN 2 LIGANDS, CELLS PREPARED THEREWITH, AND THERAPIES USING SAME<br/>[FR] LIGANDS DE LA PROTÉINE 2 DE TYPE LANTHIONINE C, CELLULES PRÉPARÉES AVEC CEUX-CI, ET THÉRAPIES LES UTILISANT
  申请人：LANDOS BIOPHARMA INC

  公开号：WO2021127472A1

  公开（公告）日：2021-06-24

  Provided are compounds that target the lanthionine synthetase C-like protein 2 pathway. The compounds can be used to treat a number of conditions, including autoimmune diseases, inflammatory diseases, chronic inflammatory diseases, diabetes, and infectious diseases, such as lupus, rheumatoid arthritis, type 1 diabetes, inflammatory bowel disease, viral diseases, and nonalcoholic steatohepatitis. The compounds can also be used to generate cells, such as immune cells, for treating the conditions.

  提供的是靶向兰硫氨酸合成酶C样蛋白2途径的化合物。这些化合物可用于治疗多种疾病，包括自身免疫性疾病、炎症性疾病、慢性炎症性疾病、糖尿病和传染性疾病，如狼疮、类风湿性关节炎、1型糖尿病、炎症性肠病、病毒性疾病和非酒精性脂肪肝炎。这些化合物还可用于生成细胞，如免疫细胞，以治疗这些疾病。
• NOVEL OLEFIN DERIVATIVE
  申请人：Matsumura Akira

  公开号：US20150246938A1

  公开（公告）日：2015-09-03

  The object of the present invention is to provide novel compounds having ACC2 inhibiting activity. In addition, the object of the present invention is to provide a pharmaceutical composition comprising the compound. A compound of formula (I′): wherein R 1 is substituted or unsubstituted aryl etc., R 2 is each independently hydrogen, substituted or unsubstituted alkyl etc., R 3 is each independently hydrogen, substituted or unsubstituted alkyl etc., n is an integer from 0 to 3, R 12 is hydrogen, substituted or unsubstituted alkyl etc., Ring A is aromatic carbocycle or aromatic heterocycle, R 9 is substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl etc., m is an integer from 0 to 4, R 4 and R 5 is each independently hydrogen, substituted or unsubstituted alkyl etc., R 6 is substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl etc., R 13 is hydrogen, substituted or unsubstituted alkyl etc., X 5 is bond etc., R 7 is hydrogen or substituted or unsubstituted alkyl, R 8 is substituted or unsubstituted alkylcarbonyl, substituted or unsubstituted alkenylcarbonyl etc.

  本发明的目的是提供具有ACC2抑制活性的新型化合物。此外，本发明的目的是提供包含该化合物的药物组合物。 公式(I′)的化合物： 其中R1是取代或未取代的芳基等， R2各自独立为氢，取代或未取代的烷基等， R3各自独立为氢，取代或未取代的烷基等， n是0到3的整数， R12是氢，取代或未取代的烷基等， 环A是芳香碳环或芳香杂环， R9是取代或未取代的烷基，取代或未取代的烯基等， m是0到4的整数， R4和R5各自独立为氢，取代或未取代的烷基等， R6是取代或未取代的烷基，取代或未取代的烯基等， R13是氢，取代或未取代的烷基等， X5是键等， R7是氢或取代或未取代的烷基， R8是取代或未取代的烷基碳酰，取代或未取代的烯基碳酰等。
• [EN] PLXDC2 LIGANDS<br/>[FR] LIGANDS DE PLXDC2
  申请人：LANDOS BIOPHARMA INC

  公开号：WO2021195360A1

  公开（公告）日：2021-09-30

  Provided are compounds that target plexin domain containing 2 (PLXDC2). The compounds can be used to treat conditions such as inflammatory or immune-mediated diseases, diabetes, infectious diseases, and cancers. The compounds can be used to treat such specific conditions as systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, autoimmune encephalitis, diabetic nephropathy, diabetic retinopathy, psoriasis, and inflammatory bowel disease, among other conditions.

  提供了针对含有plexin结构域2（PLXDC2）的化合物。这些化合物可以用于治疗炎症或免疫介导性疾病、糖尿病、传染病和癌症等疾病。这些化合物可以用于治疗系统性红斑狼疮、类风湿关节炎、多发性硬化症、自身免疫性脑炎、糖尿病肾病、糖尿病视网膜病变、银屑病和炎症性肠病等特定疾病。
• Tetrahydrofuranyl and tetrahydrothienyl substituted ethers
  申请人：E.R. Squibb & Sons, Inc.

  公开号：EP0161904A2

  公开（公告）日：1985-11-21

  Tetrahydrofuranyl and tetrahydrothienyl substituted ethers are provided having the structural formula wherein A is (CH2)2, CH=CH or a single bond, m is 1 to 5, B is a single bond or CH = CH, n is 1 to 4, X is 0 or wherein n' is 0, 1 or 2, R is H lower alkyl or alkali metal and R' is lower alkyl, arylalkyl, aryl, cycloalkyl, cycloalkylalkyl or lower alkenyl and including all stereoisomers thereof and Y is either oxygen or sulfur. The compounds are cardiovascular agents useful, for example, in the treatment of thrombolytic disease and as antiinflammatory agents and analgesics.

  四氢呋喃基和四氢噻吩基取代醚的结构式为 其中 A 为 (CH2)2、CH=CH 或单键，m 为 1 至 5，B 为单键或 CH=CH，n 为 1 至 4，X 为 0 或 其中 n'为 0、1 或 2，R 为 H 低级烷基或碱金属，R'为低级烷基、芳烷基、芳基、环烷基、 环烷基烷基或低级烯基，包括其所有立体异构体，Y 为氧或硫。 这些化合物是心血管药物，可用于治疗血栓溶解疾病、抗炎和镇痛。
• An amide compound and its production and use
  申请人：SUMITOMO CHEMICAL COMPANY, LIMITED

  公开号：EP0394043A1

  公开（公告）日：1990-10-24

  A range of novel amide compounds represented by the formula wherein A is a group represented by the formula and the ring B is a benzene, pyridine or cyclohexane ring, are defined and their production and insecticidal and/or acaricidal properties are described.

  一系列新型酰胺化合物，由式表示 式中 A 是由式 和环 B 是苯、吡啶或环己烷环的定义，并描述了它们的生产和杀虫及/或杀螨性。